{"id":1031,"date":"2018-02-07T13:10:30","date_gmt":"2018-02-07T13:10:30","guid":{"rendered":"http:\/\/neuroeconomix.com\/?p=1031"},"modified":"2025-01-28T18:19:37","modified_gmt":"2025-01-28T23:19:37","slug":"resolucion-5269-de-2017-actualizacion-del-pos-para-el-2018","status":"publish","type":"post","link":"https:\/\/neuroeconomix.com\/en\/resolucion-5269-de-2017-actualizacion-del-pos-para-el-2018\/","title":{"rendered":"Resoluci\u00f3n 5269 de 2017:  Actualizaci\u00f3n del POS para el 2018"},"content":{"rendered":"<p>[vc_row css=\u00bb.vc_custom_1533834763111{background-color: #ffffff !important;}\u00bb][vc_column][vc_custom_heading text=\u00bbResoluci\u00f3n 5269 de 2017: Actualizaci\u00f3n del POS para el 2018&#8243; font_container=\u00bbtag:h2|text_align:center|color:%23990d0d\u00bb use_theme_fonts=\u00bbyes\u00bb][vc_row_inner content_placement=\u00bbmiddle\u00bb][vc_column_inner width=\u00bb1\/4&#8243;][\/vc_column_inner][vc_column_inner width=\u00bb1\/4&#8243;][vc_single_image image=\u00bb1871&#8243; img_size=\u00bb110&#215;110&#8243; alignment=\u00bbcenter\u00bb style=\u00bbvc_box_shadow_circle_2&#8243; css_animation=\u00bbbounceIn\u00bb][\/vc_column_inner][vc_column_inner width=\u00bb1\/4&#8243;][vc_column_text el_class=\u00bbreferencias\u00bb]<strong>Por: <\/strong><strong>Diana Gonz\u00e1lez-Bravo<\/strong><br \/>\nMD, Epidemi\u00f3logo<br \/>\nInvestigador MBE<br \/>\nNeuroeconomix[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00bb1\/4&#8243;][\/vc_column_inner][\/vc_row_inner][vc_column_text]<\/p>\n<h4 style=\"text-align: center;\"><strong><span style=\"color: #000000;\">La resoluci\u00f3n 5269 de\u00a02017 actualiza el POS para el 2018 en cuanto a tecnolog\u00edas (medicamentos, dispositivos o procedimientos) que ser\u00e1n incluidas. Aqu\u00ed le explicamos qu\u00e9 cambi\u00f3 y d\u00f3nde la puede consultar.<\/span><\/strong><\/h4>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]El objetivo de la resoluci\u00f3n 5269 de 2017 es <span style=\"color: #ffbf00;\"><strong>actualizar integralmente el plan de beneficios en salud con cargo a la UPC<\/strong><\/span>, con el fin de ampliar y definir la cobertura nacional de los servicios y tecnolog\u00edas en salud, los cuales deber\u00e1n ser garantizados por las entidades prestadoras de salud (EPS o quienes hagan sus veces) a los afiliados del SGSSS.<\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #9b0707;\"><strong>\u00bfQu\u00e9 contiene esta resoluci\u00f3n?<\/strong><\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #9b0707;\"><strong>Anexo 1 <\/strong><\/span>\u201cListado de <span style=\"color: #ffbf00;\"><strong>medicamentos<\/strong><\/span> del Plan de Beneficios en Salud con cargo a la UPC\u201d,<\/p>\n<p><span style=\"color: #9b0707;\"><strong>Anexo 2<\/strong><\/span> \u201cListado de <span style=\"color: #ffbf00;\"><strong>procedimientos<\/strong> <\/span>en salud del Plan de Beneficios en Salud con cargo a la UPC\u201d,<\/p>\n<p><span style=\"color: #9b0707;\"><strong>Anexo 3<\/strong><\/span> \u201cListado de procedimientos de <span style=\"color: #ffbf00;\"><strong>laboratorio cl\u00ednico<\/strong><\/span> del Plan de Beneficios en Salud con cargo a la UPC\u201d.<\/p>\n<p>&nbsp;<\/p>\n<p><strong><span style=\"color: #9b0707;\">\u00bfY, qu\u00e9 cambi\u00f3?<\/span> <\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>Son <span style=\"color: #ffbf00;\"><strong>112 inclusiones <\/strong><\/span>(78 medicamentos, 32 procedimientos y 2 dispositivos m\u00e9dicos). Eso se traduce a que en la pr\u00e1ctica son <span style=\"color: #ffbf00;\"><strong>278 nuevas opciones terap\u00e9uticas<\/strong><\/span>, varias con m\u00e1s de una indicaci\u00f3n aprobada, <span style=\"color: #ffbf00;\"><strong>para el tratamiento y la atenci\u00f3n de 137 patolog\u00edas.<\/strong><\/span><\/p>\n<p>&nbsp;<\/p>\n<p>Cap\u00edtulo IV, art\u00edculo 38. El plan de beneficios en salud con cargo a la UPC financia los medicamentos de acuerdo con las siguientes <span style=\"color: #ffbf00;\"><strong>condiciones<\/strong>:<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>1. Principio activo, concentraci\u00f3n, forma farmac\u00e9utica y uso espec\u00edfico en los casos en los que se encuentre descrito en el anexo 1, que hace parte integral de este acto administrativo.<\/p>\n<p>&nbsp;<\/p>\n<p><i>2.\u00a0<\/i>Para la <span style=\"color: #ffbf00;\"><strong>financiaci\u00f3n<\/strong><\/span>, deben <span style=\"color: #ffbf00;\"><strong>coincidir todas<\/strong><\/span> estas condiciones seg\u00fan como se encuentren descritas en el listado. Sin embargo, la menci\u00f3n de \u00e9stas tecnolog\u00edas en Gu\u00edas de pr\u00e1ctica Cl\u00ednica, Gu\u00edas de Atenci\u00f3n Integral, Normas T\u00e9cnicas y protocolos, <span style=\"color: #ffbf00;\"><strong>NO implica su financiaci\u00f3n con recursos de la UPC <\/strong><\/span>(par\u00e1grafo del art\u00edculo 4, t\u00edtulo I).<\/p>\n<p>&nbsp;<\/p>\n<p><u>\u200b<\/u>Para m\u00e1s informaci\u00f3n,<\/p>\n<p>&nbsp;<\/p>\n<p>descargue <span style=\"color: #9b0707;\"><strong><a style=\"color: #9b0707;\" href=\"http:\/\/neuroeconomix.com\/wp-content\/uploads\/2018\/02\/nuevo_plan_de_beneficios_para_el_2018_-_resolucion_5269_de_2017-1.pdf\">AQU\u00cd<\/a><\/strong><\/span> el pdf <em>Plan de Beneficios 2018 &#8211; Resoluci\u00f3n 5269 de 2017<\/em>.<\/p>\n<p>&nbsp;<\/p>\n<p>Haga clik\u00a0\u00a0<span style=\"color: #9b0707;\"><strong><span style=\"color: #9b0707;\"><a style=\"color: #9b0707;\" href=\"http:\/\/neuroeconomix.com\/nuevo-pos-que-fue-lo-que-cambio\/\" target=\"_blank\" rel=\"noopener\">AQU\u00cd<\/a>\u00a0<\/span> \u00a0<\/strong><\/span>para ver informaci\u00f3n sobre el POS actual 2019<\/p>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row css=\u00bb.vc_custom_1533834763111{background-color: #ffffff !important;}\u00bb][vc_column][vc_custom_heading text=\u00bbResoluci\u00f3n 5269 de 2017: Actualizaci\u00f3n del POS para el 2018&#8243; font_container=\u00bbtag:h2|text_align:center|color:%23990d0d\u00bb use_theme_fonts=\u00bbyes\u00bb][vc_row_inner content_placement=\u00bbmiddle\u00bb][vc_column_inner width=\u00bb1\/4&#8243;][\/vc_column_inner][vc_column_inner width=\u00bb1\/4&#8243;][vc_single_image image=\u00bb1871&#8243; img_size=\u00bb110&#215;110&#8243; alignment=\u00bbcenter\u00bb style=\u00bbvc_box_shadow_circle_2&#8243; css_animation=\u00bbbounceIn\u00bb][\/vc_column_inner][vc_column_inner width=\u00bb1\/4&#8243;][vc_column_text&#8230;<\/p>\n","protected":false},"author":19,"featured_media":2170,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[4,6],"tags":[60,61,62,63,53,64,65],"ppma_author":[740],"class_list":["post-1031","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","category-news-sgsss","tag-anexos","tag-cargos-a-la-upc","tag-inclusiones","tag-laboratorio-clinico","tag-medicamentos","tag-pos","tag-resolucion-5269-de-2017"],"taxonomy_info":{"category":[{"value":4,"label":"Blogs Publicados"},{"value":6,"label":"Novedades SGSSS"}],"post_tag":[{"value":60,"label":"anexos"},{"value":61,"label":"cargos a la UPC"},{"value":62,"label":"inclusiones"},{"value":63,"label":"laboratorio cl\u00ednico"},{"value":53,"label":"medicamentos"},{"value":64,"label":"POS"},{"value":65,"label":"Resoluci\u00f3n 5269 de 2017"}]},"featured_image_src_large":["https:\/\/neuroeconomix.com\/wp-content\/uploads\/2018\/02\/resolucion-1.jpg",370,500,false],"author_info":{"display_name":"NeuroEconomix","author_link":"https:\/\/neuroeconomix.com\/en\/author\/wpnotifs\/"},"comment_info":8,"category_info":[{"term_id":4,"name":"Blogs Publicados","slug":"blog","term_group":0,"term_taxonomy_id":4,"taxonomy":"category","description":"","parent":0,"count":251,"filter":"raw","cat_ID":4,"category_count":251,"category_description":"","cat_name":"Blogs Publicados","category_nicename":"blog","category_parent":0},{"term_id":6,"name":"Novedades SGSSS","slug":"news-sgsss","term_group":0,"term_taxonomy_id":6,"taxonomy":"category","description":"","parent":0,"count":45,"filter":"raw","cat_ID":6,"category_count":45,"category_description":"","cat_name":"Novedades SGSSS","category_nicename":"news-sgsss","category_parent":0}],"tag_info":[{"term_id":60,"name":"anexos","slug":"anexos","term_group":0,"term_taxonomy_id":60,"taxonomy":"post_tag","description":"","parent":0,"count":1,"filter":"raw"},{"term_id":61,"name":"cargos a la UPC","slug":"cargos-a-la-upc","term_group":0,"term_taxonomy_id":61,"taxonomy":"post_tag","description":"","parent":0,"count":2,"filter":"raw"},{"term_id":62,"name":"inclusiones","slug":"inclusiones","term_group":0,"term_taxonomy_id":62,"taxonomy":"post_tag","description":"","parent":0,"count":1,"filter":"raw"},{"term_id":63,"name":"laboratorio cl\u00ednico","slug":"laboratorio-clinico","term_group":0,"term_taxonomy_id":63,"taxonomy":"post_tag","description":"","parent":0,"count":1,"filter":"raw"},{"term_id":53,"name":"medicamentos","slug":"medicamentos","term_group":0,"term_taxonomy_id":53,"taxonomy":"post_tag","description":"","parent":0,"count":58,"filter":"raw"},{"term_id":64,"name":"POS","slug":"pos","term_group":0,"term_taxonomy_id":64,"taxonomy":"post_tag","description":"","parent":0,"count":14,"filter":"raw"},{"term_id":65,"name":"Resoluci\u00f3n 5269 de 2017","slug":"resolucion-5269-de-2017","term_group":0,"term_taxonomy_id":65,"taxonomy":"post_tag","description":"","parent":0,"count":1,"filter":"raw"}],"authors":[{"term_id":740,"user_id":19,"is_guest":0,"slug":"wpnotifs","display_name":"NeuroEconomix","avatar_url":"https:\/\/neuroeconomix.com\/wp-content\/uploads\/2025\/01\/neuroeconomix-home-testimonials.svg","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/neuroeconomix.com\/en\/wp-json\/wp\/v2\/posts\/1031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neuroeconomix.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neuroeconomix.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neuroeconomix.com\/en\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/neuroeconomix.com\/en\/wp-json\/wp\/v2\/comments?post=1031"}],"version-history":[{"count":1,"href":"https:\/\/neuroeconomix.com\/en\/wp-json\/wp\/v2\/posts\/1031\/revisions"}],"predecessor-version":[{"id":14443,"href":"https:\/\/neuroeconomix.com\/en\/wp-json\/wp\/v2\/posts\/1031\/revisions\/14443"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neuroeconomix.com\/en\/wp-json\/wp\/v2\/media\/2170"}],"wp:attachment":[{"href":"https:\/\/neuroeconomix.com\/en\/wp-json\/wp\/v2\/media?parent=1031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neuroeconomix.com\/en\/wp-json\/wp\/v2\/categories?post=1031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neuroeconomix.com\/en\/wp-json\/wp\/v2\/tags?post=1031"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/neuroeconomix.com\/en\/wp-json\/wp\/v2\/ppma_author?post=1031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}